The Definitive Peptide Research Reference Guide — Compound Review

Home Compounds BPC-157 TB-500 CJC-1295 Ipamorelin GLP-1 GHK-Cu Epithalon NAD+ Comparisons BPC-157 vs TB-500 Sermorelin vs Ipamorelin Semaglutide vs Tirzepatide Guides GHK-Cu Guide GHRH Analogues Ipamorelin Guide Peptide Reconstitution Guide Peptide Injection Sites Guide Peptide Storage Guide Semaglutide Dosage BPC-157 Dosage Research Guides Joint Pain Weight Loss Longevity Vendor Scoreboard All Vendor Comparisons Peptide Price Comparison Vendor Closures & Status How to Read a Peptide COA How to Vet a Peptide Vendor Why Purgo Labs Purgo Labs Review Purgo Labs Discount Code Where to Buy by Compound Legal Status Shop Purgo Labs

Semaglutide Dosage for Women

Semaglutide dosage for women: sex-specific GLP-1 response, research protocols, and metabolic considerations.

STEP Trial Data: What It Shows for Women

Semaglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Ozempic, 0.5–2 mg weekly) and chronic weight management (Wegovy, up to 2.4 mg weekly). In women, GLP-1 receptor agonism reduces appetite through hypothalamic signaling, slows gastric emptying, and improves insulin sensitivity. The STEP-1 trial (Wegovy) demonstrated 14.9% mean body weight reduction over 68 weeks in adults with obesity — with similar efficacy across sexes.

Titration Schedule & GI Management for Women

For women using semaglutide for weight management, the FDA-approved Wegovy protocol titrates from 0.25 mg weekly for 4 weeks, increasing by 0.25 mg every 4 weeks to a maintenance dose of 2.4 mg weekly. The titration schedule minimizes GI side effects (nausea, vomiting, diarrhea) which are the primary tolerability concern. Women with PCOS may see additional benefits through improved insulin sensitivity and androgen reduction.

Women-Specific Considerations

Semaglutide is contraindicated in pregnancy and breastfeeding. Women of reproductive age should use effective contraception, as weight loss can restore ovulation in women with obesity-related anovulation. Thyroid C-cell tumor risk (observed in rodents) has not been confirmed in humans but remains a contraindication in those with personal or family history of medullary thyroid carcinoma or MEN2.